<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047202</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-PanFlu-4003</org_study_id>
    <nct_id>NCT01047202</nct_id>
  </id_info>
  <brief_title>Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants</brief_title>
  <official_title>A Blinded, Randomized and Controlled Clinical Trial With Influenza A/H1N1 Split-virion Vaccine in 6 to 35 Months Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <brief_summary>
    <textblock>
      A single center, observer-masked, randomized clinical trial is to be conducted in 6-35 months
      infants to evaluate the safety and immunogenicity of Sinovac's influenza A/H1N1 Vaccine
      (PANFLU.1).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in infants</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in infants</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 subjects to receive two doses of 7.5 μg pandemic influenza A/H1N1 vaccine 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : 15 μg pandemic influenza A/H1N1 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 subjects to receive two doses of 15 μg pandemic influenza A/H1N1 vaccine 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 : 7.5 μg seasonal trivalent vaccine</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>60 subjects to receive two doses of 7.5 μg seasonal trivalent vaccine 21 days apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pandemic influenza A/H1N1 vaccine</intervention_name>
    <description>Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose</description>
    <arm_group_label>Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pandemic influenza A/H1N1 vaccine</intervention_name>
    <description>Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose</description>
    <arm_group_label>Group 2 : 15 μg pandemic influenza A/H1N1 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal trivalent vaccine</intervention_name>
    <description>Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose</description>
    <arm_group_label>Group 3 : 7.5 μg seasonal trivalent vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female aged between 6 and 35 months

          2. Full-term birth, birth weight 2,500 grams or more

          3. provided birth certification or vaccination card Parent(s) or legal guardian(s) are
             able to understand and sign the informed consent

        Exclusion Criteria:

          1. Cases, cured cases and close contact of influenza A (H1N1) virus

          2. Subject that has a medical history of any of the following: allergic history, or
             allergic to any ingredient of vaccine, such as egg, egg protein, etc

          3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory
             difficulty, angioedema, or abdominal pain

          4. Symptoms of acute infection within a week

          5. Autoimmune disease or immunodeficiency

          6. Congenital malformation, developmental disorders or serious chronic diseases (such as
             Down's syndrome, diabetes, sickle cell anemia or neurological disorders)

          7. Asthma that is unstable or required emergent care, hospitalization or intubation
             during the past two years or that required the use of oral or intravenous
             corticosteroids

          8. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or
             platelet disorder requiring special precautions) or significant bruising or bleeding
             difficulties with IM injections or blood draws

          9. History or family history of convulsions, epilepsy, brain disease and psychiatric

         10. Asplenia, functional asplenia or any condition resulting in the absence or removal o
             the spleen

         11. Guillain-Barre Syndrome

         12. Administration of 2009-2010 seasonal vaccine

         13. History of any blood products within 3 months

         14. Administration of any other investigational research agents within 30 days

         15. Administration of any live attenuated vaccine within 30 days

         16. Administration of subunit or inactivated vaccines within 14 days

         17. Be receiving anti-TB prophylaxis or therapy currently

         18. Axillary temperature &gt; 37.0 centigrade at the time of dosing

         19. Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>GuangXi Center for Diseases Control and Prevention</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

